Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 108Ovarian Neoplasms 64Neoplasms 61Fallopian Tube Neoplasms 40Lung Neoplasms 37Breast Neoplasms 33Neoplasm Metastasis 25Carcinoma, Ovarian Epithelial 25Triple Negative Breast Neoplasms 21Small Cell Lung Carcinoma 20Esophageal Neoplasms 19Endometrial Neoplasms 19Colorectal Neoplasms 15Advanced Solid Tumors 14Squamous Cell Carcinoma of Head and Neck 13Lymphoma, Large B-Cell, Diffuse 13Unspecified Adult Solid Tumor, Protocol Specific 12Stomach Neoplasms 11Melanoma 11Central Nervous System Neoplasms 11Uterine Cervical Neoplasms 10Pancreatic Neoplasms 10Astrocytoma 10Neuroblastoma 9Medulloblastoma 9Head and Neck Neoplasms 9Carcinoma 9Urinary Bladder Neoplasms 8Solid Tumors 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8

Interventions

sapanisertib 1Taxes 1Paclitaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Recurrent Malignant Solid Neoplasm × Carboplatin × Clear all
NCT03430882 2022-06-21

Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Completed
35 enrolled
Other solid neoplasm

Recurrent Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡